GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kyorin Pharmaceutical Co Ltd (TSE:4569) » Definitions » EV-to-EBITDA

Kyorin Pharmaceutical Co (TSE:4569) EV-to-EBITDA : 16.25 (As of May. 22, 2024)


View and export this data going back to 2001. Start your Free Trial

What is Kyorin Pharmaceutical Co EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Kyorin Pharmaceutical Co's enterprise value is 円100,103 Mil. Kyorin Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was 円6,160 Mil. Therefore, Kyorin Pharmaceutical Co's EV-to-EBITDA for today is 16.25.

The historical rank and industry rank for Kyorin Pharmaceutical Co's EV-to-EBITDA or its related term are showing as below:

TSE:4569' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.87   Med: 12.16   Max: 19.41
Current: 16.25

During the past 13 years, the highest EV-to-EBITDA of Kyorin Pharmaceutical Co was 19.41. The lowest was 4.87. And the median was 12.16.

TSE:4569's EV-to-EBITDA is ranked worse than
55.73% of 716 companies
in the Drug Manufacturers industry
Industry Median: 14.56 vs TSE:4569: 16.25

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-22), Kyorin Pharmaceutical Co's stock price is 円1714.00. Kyorin Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was 円74.268. Therefore, Kyorin Pharmaceutical Co's PE Ratio for today is 23.08.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Kyorin Pharmaceutical Co EV-to-EBITDA Historical Data

The historical data trend for Kyorin Pharmaceutical Co's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyorin Pharmaceutical Co EV-to-EBITDA Chart

Kyorin Pharmaceutical Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.33 10.09 8.47 10.67 9.21

Kyorin Pharmaceutical Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.02 9.21 16.48 13.26 16.82

Competitive Comparison of Kyorin Pharmaceutical Co's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Kyorin Pharmaceutical Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kyorin Pharmaceutical Co's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kyorin Pharmaceutical Co's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Kyorin Pharmaceutical Co's EV-to-EBITDA falls into.



Kyorin Pharmaceutical Co EV-to-EBITDA Calculation

Kyorin Pharmaceutical Co's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=100103.217/6160
=16.25

Kyorin Pharmaceutical Co's current Enterprise Value is 円100,103 Mil.
Kyorin Pharmaceutical Co's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円6,160 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kyorin Pharmaceutical Co  (TSE:4569) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Kyorin Pharmaceutical Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1714.00/74.268
=23.08

Kyorin Pharmaceutical Co's share price for today is 円1714.00.
Kyorin Pharmaceutical Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円74.268.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Kyorin Pharmaceutical Co EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Kyorin Pharmaceutical Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Kyorin Pharmaceutical Co (TSE:4569) Business Description

Traded in Other Exchanges
N/A
Address
6, Kanda Surugadai 4-chome, Chiyoda-ku, Tokyo, JPN, 101-8311
Kyorin Pharmaceutical Co Ltd is engaged in manufacturing and sale of pharmaceutical products. The company manages its business in two reportable segments namely Pharmaceutical Business and the Consumer Healthcare (Skincare) Business. The Pharmaceutical business focuses on producing and selling ethical drugs, generic drugs and over-the-counter drugs. The Consumer Healthcare (Skincare) Business mainly sells and purchases skincare products. The company's products include Kipres, for treating bronchial asthma and allergic rhinitis; Mucodyne, a mucoregulant; Pentasa, for treating ulcerative colitis and Crohn's disease; and Uritos, for treating overactive bladder. Majority of the company's revenue comes from domestic sales.

Kyorin Pharmaceutical Co (TSE:4569) Headlines

No Headlines